San Francisco Bay Area-based biopharma company Glialogix has entered into a sponsored research agreement with the Multiple Sclerosis Society’s Fast Forward nonprofit that works to accelerate the development of treatments for multiple sclerosis.
The agreement will see Fast Forward provide funding to Glialogix for preclinical trials of its GLX1112 therapy that directly protects neurons to slow the accumulation of disability in progressive MS, in which chronic neurodegeneration occurs resulting in a steady accumulation of disability. Presently, drugs that are effective in treating cases of relapsing multiple sclerosis have little to no efficacy in progressive multiple sclerosis.
Approved therapies for relapsing MS primarily target the peripheral immune system, while Glialogix claims that its GLX1112 therapy protects neurons directly. The neuroprotective function of GLX1112 may also be useful in treating other neurodegenerative diseases.
Further research funded by Fast Forward will include advanced pharmacokinetic testing preclinical models and mechanistic studies of the GLX1112 oral therapy.
Glialogix, Fast Forward Partner for MS Therapies
Glialogix has partnered with the National Multiple Sclerosis Society’s Fast Forward nonprofit to develop treatment therapies for progressive MS, including the acceleration of clinical trials of its GLX1112 oral therapy.
You’ve read {{metering-count}} of {{metering-total}} articles this month.
We want you to take advantage of everything Neurology Advisor has to offer. To view unlimited content, log in or register for free.
{{login-button}} {{register-button}}
Want to view more content from Neurology Advisor?
Register now at no charge to access unlimited clinical news with personalized daily picks for you, full-length features, case studies, conference coverage, and more.
{{login-button}} {{register-button}}
Want to read more?
Please login or register first to view this content.